$ 7.14
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.
Target Price
The average target price of KYTX is 21 and suggests 195% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
